Source:http://linkedlifedata.com/resource/pubmed/id/10615232
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2000-1-4
|
pubmed:abstractText |
This retrospective study of ovarian cancer aimed to elucidate whether expression of apoptosis-related proteins, bcl-2, p53 or MDM-2, is associated with resistance to chemotherapy, especially cisplatin (CDDP) based chemotherapy. Expression of bcl-2, p53 and MDM-2 was assessed by immunohistochemical staining of tumour tissues collected at initial surgery prior to treatment with CDDP-based chemotherapy. Among 66 patients with advanced ovarian cancer with measurable tumour following surgery and evaluable for response to chemotherapy, 42, 45 and 56% were positive for bcl-2, p53 and MDM-2, respectively. Significantly fewer tumours of patients who had a complete response to chemotherapy (CR) showed positivity for bcl-2 (2/20) than for p53 (6/20) and MDM-2 (8/20, P < 0.001). There was an inverse correlation between bcl-2 staining and initial response to chemotherapy, especially in serous and endometrial adenocarcinomas. In patients with stage III-IV, serous or endometrioid adenocarcinomas, significantly poorer survival was seen for those with bcl-2 positive tumours than those with negative bcl-2 staining (P = 0.0064). p53 and MDM-2 were not correlated with initial response to chemotherapy. Multivariate analysis revealed that bcl-2, residual tumour size and histology were significant independent prognostic factors. These results suggest that bcl-2 can be a possible predictor of response to chemotherapy and prognosis in patients with advanced ovarian carcinoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/MDM2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-mdm2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0959-8049
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
35
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1214-9
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10615232-Antineoplastic Agents,
pubmed-meshheading:10615232-Cisplatin,
pubmed-meshheading:10615232-Drug Resistance, Multiple,
pubmed-meshheading:10615232-Drug Resistance, Neoplasm,
pubmed-meshheading:10615232-Female,
pubmed-meshheading:10615232-Humans,
pubmed-meshheading:10615232-Multivariate Analysis,
pubmed-meshheading:10615232-Neoplasm Proteins,
pubmed-meshheading:10615232-Nuclear Proteins,
pubmed-meshheading:10615232-Ovarian Neoplasms,
pubmed-meshheading:10615232-Proto-Oncogene Proteins,
pubmed-meshheading:10615232-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:10615232-Proto-Oncogene Proteins c-mdm2,
pubmed-meshheading:10615232-Retrospective Studies,
pubmed-meshheading:10615232-Survival Analysis,
pubmed-meshheading:10615232-Tumor Suppressor Protein p53
|
pubmed:year |
1999
|
pubmed:articleTitle |
Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer.
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, National Defense Medical College, Saitama, Japan.
|
pubmed:publicationType |
Journal Article
|